Upsher-Smith Laboratories, Inc. announced Monday that a new savings and support program is available for patients who have been prescribed Qudexy XR extended-release capsules.
“We are pleased to introduce this new savings and support program so that even more patients can experience the benefits of Qudexy XR,” chief commercial officer of Upsher-Smith Rusty Field said. “This program is designed to provide cost-savings support to patients while reducing the amount of time that it takes for health care professionals to process prior authorizations.”
The savings and support program includes a free trial offer of a 30-day supply of Qudexy when patients fill their first prescription; a co-pay program in which eligible patients pay a maximum of $10 per month for their next 12 prescriptions and can save up to $200 per month; and a pharmacy-based prior authorization program to reduce the time it takes for patients to access their prescriptions.
The Qudexy XR Patient Savings and Support Program is offered to cash-paying and commercially insured patients. Eligible patients can acquire a Qudexy Patient Savings Folder from their physicians, which includes a co-pay savings card and the 30-day trial.
Qudexy XR is used at initial monotherapy in patients 10 and older with Partial Onset Seizures (POS) or primary generalized tonic-clonic seizures. It is also used as an adjunctive therapy in patients 2 and older with POS, seizures associated with Lennox-Gastaut syndrome and generalized tonic-clonic seizures.
Alerts Sign-up